Novartis petitions FDA to block 18 generic competitors for its megablockbuster heart drug until 2024
Novartis is looking to milk one of its most prized possessions a little while longer without any generic competition, mostly because of a newly approved …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
